Clinical Trials Browser

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

Clinical Trials

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

GCISAVE

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

RECIPE-B1

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

DISCUS

Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

ARID1A and/or KDM6A Mutation and CXCL13 Expression

TOMBOLA

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

DutaBCa-1

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

NeuroPrevPTSD

TRIFECTA

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Bristol Bladder Trial

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Telehealth Intervention for Ostomy Self-Management

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Intravesical Gem/Doce in Patients With NMIBC

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Renal Retention in High Grade Upper Tract Urothelial Cancer

NEXT

Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

NEOBLAST

FUTURE

BCIRT-01

BladderSpar

GEMDOCE

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

RAD-VACCINE

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder